Critical review of antipsychotic polypharmacy in the treatment of schizophrenia

W. Wolfgang Fleischhacker, Hiroyuki Uchida

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Antipsychotic polypharmacy remains prevalent; it has probably increased for the treatment of schizophrenia in real-world clinical settings. The current evidence suggests some clinical benefits of antipsychotic polypharmacy, such as better symptom control with clozapine plus another antipsychotic, and a reversal of metabolic side-effects with a concomitant use of aripiprazole. On the other hand, the interpretation of findings in the literature should be made conservatively in light of the paucity of good studies and potentially serious side-effects. Also, although the available data are still limited, two smaller-scale clinical trials provide preliminary evidence that converting antipsychotic polypharmacy to monotherapy could be a valid and reasonable treatment option. Several studies have explored strategies to change physicians' antipsychotic polypharmacy prescribing behaviours. These have revealed that, while the impact of purely educational interventions may be limited, more aggressive procedures such as directly notifying physicians by letters or phone calls can be more effective in reducing antipsychotic polypharmacy. In conclusion, antipsychotic polypharmacy can work for some clinically difficult conditions; however, it should be the exception rather than the rule and may be avoidable in many patients. More importantly, the paucity of the data clearly emphasizes the need for further investigations on not only advantages and disadvantages of antipsychotic polypharmacy, but also regarding effective interventions in already prescribed polypharmacy regimens.

Original languageEnglish
Pages (from-to)1083-1093
Number of pages11
JournalInternational Journal of Neuropsychopharmacology
Volume17
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Polypharmacy
Antipsychotic Agents
Schizophrenia
Therapeutics
Physicians
Clozapine
Clinical Trials

Keywords

  • Add-on treatment
  • adjunctive treatment
  • antipsychotic
  • combination
  • polypharmacy
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. / Fleischhacker, W. Wolfgang; Uchida, Hiroyuki.

In: International Journal of Neuropsychopharmacology, Vol. 17, No. 7, 2014, p. 1083-1093.

Research output: Contribution to journalArticle

@article{6befe41f545e41ef8daf0b66e3e19402,
title = "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia",
abstract = "Antipsychotic polypharmacy remains prevalent; it has probably increased for the treatment of schizophrenia in real-world clinical settings. The current evidence suggests some clinical benefits of antipsychotic polypharmacy, such as better symptom control with clozapine plus another antipsychotic, and a reversal of metabolic side-effects with a concomitant use of aripiprazole. On the other hand, the interpretation of findings in the literature should be made conservatively in light of the paucity of good studies and potentially serious side-effects. Also, although the available data are still limited, two smaller-scale clinical trials provide preliminary evidence that converting antipsychotic polypharmacy to monotherapy could be a valid and reasonable treatment option. Several studies have explored strategies to change physicians' antipsychotic polypharmacy prescribing behaviours. These have revealed that, while the impact of purely educational interventions may be limited, more aggressive procedures such as directly notifying physicians by letters or phone calls can be more effective in reducing antipsychotic polypharmacy. In conclusion, antipsychotic polypharmacy can work for some clinically difficult conditions; however, it should be the exception rather than the rule and may be avoidable in many patients. More importantly, the paucity of the data clearly emphasizes the need for further investigations on not only advantages and disadvantages of antipsychotic polypharmacy, but also regarding effective interventions in already prescribed polypharmacy regimens.",
keywords = "Add-on treatment, adjunctive treatment, antipsychotic, combination, polypharmacy, schizophrenia",
author = "Fleischhacker, {W. Wolfgang} and Hiroyuki Uchida",
year = "2014",
doi = "10.1017/S1461145712000399",
language = "English",
volume = "17",
pages = "1083--1093",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "7",

}

TY - JOUR

T1 - Critical review of antipsychotic polypharmacy in the treatment of schizophrenia

AU - Fleischhacker, W. Wolfgang

AU - Uchida, Hiroyuki

PY - 2014

Y1 - 2014

N2 - Antipsychotic polypharmacy remains prevalent; it has probably increased for the treatment of schizophrenia in real-world clinical settings. The current evidence suggests some clinical benefits of antipsychotic polypharmacy, such as better symptom control with clozapine plus another antipsychotic, and a reversal of metabolic side-effects with a concomitant use of aripiprazole. On the other hand, the interpretation of findings in the literature should be made conservatively in light of the paucity of good studies and potentially serious side-effects. Also, although the available data are still limited, two smaller-scale clinical trials provide preliminary evidence that converting antipsychotic polypharmacy to monotherapy could be a valid and reasonable treatment option. Several studies have explored strategies to change physicians' antipsychotic polypharmacy prescribing behaviours. These have revealed that, while the impact of purely educational interventions may be limited, more aggressive procedures such as directly notifying physicians by letters or phone calls can be more effective in reducing antipsychotic polypharmacy. In conclusion, antipsychotic polypharmacy can work for some clinically difficult conditions; however, it should be the exception rather than the rule and may be avoidable in many patients. More importantly, the paucity of the data clearly emphasizes the need for further investigations on not only advantages and disadvantages of antipsychotic polypharmacy, but also regarding effective interventions in already prescribed polypharmacy regimens.

AB - Antipsychotic polypharmacy remains prevalent; it has probably increased for the treatment of schizophrenia in real-world clinical settings. The current evidence suggests some clinical benefits of antipsychotic polypharmacy, such as better symptom control with clozapine plus another antipsychotic, and a reversal of metabolic side-effects with a concomitant use of aripiprazole. On the other hand, the interpretation of findings in the literature should be made conservatively in light of the paucity of good studies and potentially serious side-effects. Also, although the available data are still limited, two smaller-scale clinical trials provide preliminary evidence that converting antipsychotic polypharmacy to monotherapy could be a valid and reasonable treatment option. Several studies have explored strategies to change physicians' antipsychotic polypharmacy prescribing behaviours. These have revealed that, while the impact of purely educational interventions may be limited, more aggressive procedures such as directly notifying physicians by letters or phone calls can be more effective in reducing antipsychotic polypharmacy. In conclusion, antipsychotic polypharmacy can work for some clinically difficult conditions; however, it should be the exception rather than the rule and may be avoidable in many patients. More importantly, the paucity of the data clearly emphasizes the need for further investigations on not only advantages and disadvantages of antipsychotic polypharmacy, but also regarding effective interventions in already prescribed polypharmacy regimens.

KW - Add-on treatment

KW - adjunctive treatment

KW - antipsychotic

KW - combination

KW - polypharmacy

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84901476875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901476875&partnerID=8YFLogxK

U2 - 10.1017/S1461145712000399

DO - 10.1017/S1461145712000399

M3 - Article

VL - 17

SP - 1083

EP - 1093

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 7

ER -